Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Treasury Shares (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Treasury Shares for 4 consecutive years, with $278347.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares fell 46.2% year-over-year to $278347.0, compared with a TTM value of $278347.0 through Sep 2025, down 46.2%, and an annual FY2024 reading of $414470.0, up 65.32% over the prior year.
  • Treasury Shares was $278347.0 for Q3 2025 at Atara Biotherapeutics, down from $503640.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $16.5 million in Q1 2024 and bottomed at $250709.0 in Q4 2023.
  • Average Treasury Shares over 4 years is $5.2 million, with a median of $6.7 million recorded in 2022.
  • The sharpest move saw Treasury Shares tumbled 96.26% in 2023, then skyrocketed 65.32% in 2024.
  • Year by year, Treasury Shares stood at $6.7 million in 2022, then crashed by 96.26% to $250709.0 in 2023, then surged by 65.32% to $414470.0 in 2024, then plummeted by 32.84% to $278347.0 in 2025.
  • Business Quant data shows Treasury Shares for ATRA at $278347.0 in Q3 2025, $503640.0 in Q2 2025, and $677948.0 in Q1 2025.